Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK
HONG KONG, Sep 13, 2023 – (ACN Newswire via SEAPRWire.com) – Wuhan YZY Biopharma Co., Ltd. (“YZY Biopharma” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2496.HK), a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases, announced the proposed listing of its […]